

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

05 JUL 15 AM 11:24

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Arent Fox PLLC			
2. Address <input type="checkbox"/> Check if different than previously reported 1050 Connecticut Ave., N.W. Washington, D.C. 20036-5339			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Michael J. Kurman	Telephone 202/857-6345	E-mail (optional)	5. Senate ID # 4208-2474
7. Client Name <input type="checkbox"/> Self sanofi pasteur (formerly: Aventis Pasteur) (see line #20 re: name change)			6. House ID # 30861177

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 31)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇒ Termination Date _____11. No Lobbying Activities **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>40,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6011 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
--	---

Signature _____

Printed Name and Title Michael J. Kurman, Member

LD-2 (REV. 6/98)



Registrant Name Arent Fox PLLC Client Name sanofi pasteur (formerly: Aventis Pasteur) (see li name change)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- Childhood immunization
- Vaccine Injury Compensation Program
- Miscellaneous vaccination issues

17. House(s) of Congress and Federal agencies contacted

Check if None

- House of Representatives
- Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Dale Bumpers	
Gordon Taylor	Chief of Staff to Rep. Chris John (D-LA)

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Sanofi-aventis Group, identified at line #27 herein, is interested in U.S. vaccination policies that may affect the busine sanofi pasteur.

Signature _____ Date _____



Registrant Name Arent Fox PLLC Client Name sanofi pasteur (formerly: Aventis Pasteur) (see li name change)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Interpretation of SEC Rule SAB-101 in connection with stockpiling of vaccines

17. House(s) of Congress and Federal agencies contacted Check if None

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Dale Bumpers	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Sanofi-aventis Group, identified at line #27 herein, is interested in U.S. vaccination policies that may affect the busine sanofi pasteur.

Signature _____ Date _____

Registrant Name Arent Fox PLLC Client Name sanofi pasteur (formerly: Aventis Pasteur) (see lir name change)

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address Name change -- Old Name: Aventis Pasteur / New Name: sanofi pasteur
Address -- 801 Pennsylvania Avenue, N.W., Suite 725, Washington, DC 20004

21. Client new principal place of business (if different from line 20)
City Swiftwater State/Zip (or Country) PA 18370

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bu (city and state or cc)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
sanofi-aventis Group	174, av. de France 75013 Paris, France	Paris, France	-0-

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the regist affiliated organization

Connaught Laboratories Ltd.

Michael D. Surman

7/15/05

Signature Michael J. Kurman Date 1/2/00

Printed Name and Title Michael J. Kurman, Member

Form LD-2 (Rev. 6/98)

Page